Camlin Tierney

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy
    Camlin Tierney
    Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 187:144-8. 2003
  2. pmc Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
    Paul E Sax
    Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 204:1191-201. 2011
  3. pmc Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA
    J Infect Dis 207:420-5. 2013
  4. pmc HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status
    Katie Mollan
    Harvard School of Public Health, Center for Biostatistics in AIDS Research, FXB Bldg, 651 Huntington Ave, Boston, MA 02115 6017, USA
    J Infect Dis 206:1920-30. 2012
  5. pmc Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202
    Grace A McComsey
    Rainbow Babies and Children s Hospital, Case Western Reserve University, Cleveland, OH Harvard School of Public Health, Boston, MA Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA Social and Scientific Systems, Inc, Silver Spring, MD Gilead Sciences, Foster City, CA GlaxoSmithKline, Research Triangle, NC Department of Medicine, Johns Hopkins University, Baltimore, MD Frontier Science and Technology Research Foundation, Amherst, NY Department of Geriatric Medicine and Gerontology, Johns Hopkins University, Baltimore, MD Department of Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA
    J Acquir Immune Defic Syndr 65:167-74. 2014
  6. pmc Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146
    Xinyan Zhang
    Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA
    Ther Drug Monit 35:209-16. 2013
  7. pmc Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine
    Christina M Wyatt
    Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA Department of Medicine, Indiana University School of Medicine, Indianapolis, IN Department of Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA ViiV Healthcare, Research Triangle Park, NC Gilead Sciences, Foster City, CA and Department of Pediatrics, Case Western Reserve University, Cleveland, OH
    J Acquir Immune Defic Syndr 67:36-44. 2014
  8. pmc Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s
    Chris T Longenecker
    Division of Cardiovascular Medicine, Case Western Reserve University School of Medicine, Cleveland, OH Division of Infectious Diseases and Department of Pediatrics University Hospitals Case Medical Center, Cleveland, OH Department of Biostatistics, Harvard School of Public Health, Boston, MA Division of Infectious Diseases, Harvard Medical School, Boston, MA Department of Biostatistics, Brigham and Women s Hospital, Boston, MA Division of Infectious Diseases, Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, CA and Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN
    J Acquir Immune Defic Syndr 69:168-77. 2015
  9. pmc Impact of randomized antiretroviral therapy initiation on glucose metabolism
    Kristine Mace Erlandson
    aUniversity of Colorado Anschutz Medical Campus, Aurora, Colorado bHarvard School of Public Health cBrigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts dLos Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance eGilead Sciences, Foster City, California fViiV Healthcare, Research Triangle, North Carolina gCase Western Reserve University, Cleveland, Ohio, USA
    AIDS 28:1451-61. 2014
  10. pmc Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy
    Paul E Sax
    Division of Infectious Diseases and the Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 361:2230-40. 2009

Collaborators

Detail Information

Publications18

  1. ncbi request reprint Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy
    Camlin Tierney
    Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 187:144-8. 2003
    ..03). Only DNA level was significantly associated with survival (adjusted hazard ratio for 1 log(10) higher level, 3.99; 95% confidence interval, 1.44-11.09; P=.008)...
  2. pmc Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
    Paul E Sax
    Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 204:1191-201. 2011
    ..Due to higher virologic failure with ABC/3TC in the high HIV RNA stratum, blinded treatment was stopped in this group, but study follow-up continued for all patients...
  3. pmc Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA
    J Infect Dis 207:420-5. 2013
    ..005) but not among white or black participants (P = .79 and P = .46, respectively). The positive predictive value of 28*/28* for atazanavir/r discontinuation among Hispanic participants was only 32% (95% confidence interval, 16%-52%)...
  4. pmc HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status
    Katie Mollan
    Harvard School of Public Health, Center for Biostatistics in AIDS Research, FXB Bldg, 651 Huntington Ave, Boston, MA 02115 6017, USA
    J Infect Dis 206:1920-30. 2012
    ..Although specific human immunodeficiency virus type 1 (HIV-1) drug resistance mutations are well studied, little is known about cumulative amino acid changes, or how regimen and participant characteristics influence these changes...
  5. pmc Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202
    Grace A McComsey
    Rainbow Babies and Children s Hospital, Case Western Reserve University, Cleveland, OH Harvard School of Public Health, Boston, MA Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA Social and Scientific Systems, Inc, Silver Spring, MD Gilead Sciences, Foster City, CA GlaxoSmithKline, Research Triangle, NC Department of Medicine, Johns Hopkins University, Baltimore, MD Frontier Science and Technology Research Foundation, Amherst, NY Department of Geriatric Medicine and Gerontology, Johns Hopkins University, Baltimore, MD Department of Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA
    J Acquir Immune Defic Syndr 65:167-74. 2014
    ..The association of inflammatory biomarkers with clinical events after antiretroviral therapy initiation is unclear...
  6. pmc Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146
    Xinyan Zhang
    Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA
    Ther Drug Monit 35:209-16. 2013
    ..We characterized relationships between ABCB1, CYP3A4, CYP3A5, NR1I2, and SLCO1B1 polymorphisms and trough PI concentrations among AIDS Clinical Trials Group study A5146 participants...
  7. pmc Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine
    Christina M Wyatt
    Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA Department of Medicine, Indiana University School of Medicine, Indianapolis, IN Department of Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA ViiV Healthcare, Research Triangle Park, NC Gilead Sciences, Foster City, CA and Department of Pediatrics, Case Western Reserve University, Cleveland, OH
    J Acquir Immune Defic Syndr 67:36-44. 2014
    ..Antiretroviral therapy (ART) is associated with improved kidney function; however, the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir disoproxil fumarate (TDF) has been associated with decreased kidney function and proteinuria...
  8. pmc Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s
    Chris T Longenecker
    Division of Cardiovascular Medicine, Case Western Reserve University School of Medicine, Cleveland, OH Division of Infectious Diseases and Department of Pediatrics University Hospitals Case Medical Center, Cleveland, OH Department of Biostatistics, Harvard School of Public Health, Boston, MA Division of Infectious Diseases, Harvard Medical School, Boston, MA Department of Biostatistics, Brigham and Women s Hospital, Boston, MA Division of Infectious Diseases, Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, CA and Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN
    J Acquir Immune Defic Syndr 69:168-77. 2015
    ..Among patients with HIV infection, changes in the kidney filtration marker cystatin C after initiation of antiretroviral therapy (ART) may be related to changes in body composition or biomarkers of inflammation...
  9. pmc Impact of randomized antiretroviral therapy initiation on glucose metabolism
    Kristine Mace Erlandson
    aUniversity of Colorado Anschutz Medical Campus, Aurora, Colorado bHarvard School of Public Health cBrigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts dLos Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance eGilead Sciences, Foster City, California fViiV Healthcare, Research Triangle, North Carolina gCase Western Reserve University, Cleveland, Ohio, USA
    AIDS 28:1451-61. 2014
    ..Prior studies have found that early HIV protease inhibitors contribute to glucose dysregulation. Few randomized trials have evaluated glucose indices in antiretroviral-naive individuals on newer antiretroviral therapy (ART)...
  10. pmc Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy
    Paul E Sax
    Division of Infectious Diseases and the Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 361:2230-40. 2009
    ....
  11. pmc Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density
    Kristine M Erlandson
    aUniversity of Colorado Anschutz Medical Campus Aurora, Colorado bHarvard School of Public Health, Boston cBrigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts dLos Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California eUniversity of Pennsylvania, Philadelphia, Pennsylvania fGilead Sciences, Foster City, California gViiV Healthcare, Research Triangle, North Carolina hSocial and Scientific Systems, Inc, Silver Spring, Maryland iCase Western Reserve University, Cleveland, Ohio, USA
    AIDS 27:2069-79. 2013
    ..To compare the effect that initiating different antiretroviral therapy (ART) regimens has on weight, BMI, and lean body mass (LBM) and explore how changes in body composition are associated with bone mineral density (BMD)...
  12. pmc Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment
    Lei Hua
    aHarvard School of Public Health, Boston, Massachusetts bLos Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California cWeill Cornell Medical College, New York, New York, USA
    AIDS 27:2725-34. 2013
    ..To explore the relationship between hepatitis C virus (HCV)/HIV coinfection and responses to initial antiretroviral treatment (ART)...
  13. pmc A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study
    Mary Albrecht
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    HIV Clin Trials 12:201-14. 2011
    ..Secondary analyses through 48 weeks are presented...
  14. ncbi request reprint Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study
    Heather J Ribaudo
    Statistical Data Analysis Center, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 42:401-7. 2006
    ..Lower plasma efavirenz clearance is associated with a cytochrome P450 2B6 gene (CYP2B6) polymorphism (516G-->T) that is more frequent among African American individuals than among European American individuals...
  15. ncbi request reprint A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298)
    Richard B Pollard
    University of California Davis Medical Center, Patient Support Services Building, 4150 V Street, Suite G500, Sacramento, CA 95817, USA
    AIDS Res Hum Retroviruses 18:699-704. 2002
    ..Based on this study and other data, combining d4T and ZDV is not recommended...
  16. ncbi request reprint Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy
    Adriana Weinberg
    University of Colorado School of Medicine, Denver, 80262, USA
    J Infect Dis 193:488-93. 2006
    ..CMV viremia did not appear to boost CMV-specific immunity. ELISPOT assays may be used to identify HIV-infected patients who might benefit from anti-CMV prophylactic interventions...
  17. doi request reprint Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV
    Ann C Collier
    University of Washington School of Medicine and Harborview Medical Center, Seattle, Washington 98104, USA
    HIV Clin Trials 9:91-102. 2008
    ....
  18. ncbi request reprint Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study
    David W Haas
    Program for Human Genetics, Vanderbilt University School of Medicine, 345 24th Avenue North, Nashville, TN 37203, USA
    AIDS 18:2391-400. 2004
    ..Efavirenz is metabolized by cytochrome P4502B6 (CYP2B6). We investigated whether polymorphisms in CYP2B6, CYP3A4, CYP3A5, and MDR1 were associated with efavirenz central nervous system side effects and pharmacokinetics...